Syntiron LLC Receives Notification of a $3.8M Pending Contract from the United States Defense Threat Reduction Agency (DTRA) to Develop Bioterrorism Vaccines  
10/23/2008 10:38:32 AM

SAINT PAUL, Minn.--(BUSINESS WIRE)--Syntiron announced today that it was notified of a pending contract from the Defense Threat Reduction Agency (DTRA) to adapt Syntiron’s licensed, patented vaccine technology to combat three major bioterrorism agents; Bacillus anthracis, Yersinia pestis, and Burkholderia pseudomallei. The amount of the contract is $3.8 million dollars.